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The senescence of the immune system and the risk of cancer increase with aging. Age 
itself entails changes in the immune system, which are related to a decrease in thymic 
output of naïve lymphocytes, an accumulation of chronic antigenic load, notably chronic 
viral infections such as cytomegalovirus (CMV), and replicative senescence of lympho-
cytes. These changes could eventually contribute to cancer risk and affect the response 
to cancer treatment. However, several confounding factors make it difficult to draw a 
picture of causal relationships. Studies in diverse human populations could contribute 
to clarify these complex relationships. Here, we summarize the current knowledge 
about the senescence of the T cells, the relationship with CMV infection, cancer, and 
cancer treatment. We also review the results of a series of studies performed in Cuba 
whose population is characterized by the unusual combination of long life expectancy 
and high antigenic load, including high seroprevalence of CMV, typical of tropical coun-
tries. Although immunosenescence affects almost all components and functions of the 
immune response, its most salient feature is a decrease in numbers and proportions of 
naïve CD8+ T lymphocytes and an accretion of terminally differentiated CD8+ T lympho-
cytes. These features were confirmed by the Cuban studies, but interestingly a clear 
gender effect also appeared. Moreover, as aging is a global phenomenon, a fast increase 
in elderly with malignancies is expected; therefore, the evaluation of patient’s immune 
status would support the decision of treating them with immunotherapy and predict the 
efficacy of such treatments, thereby improving benefits for the patients.
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inTRODUCTiOn
Aging is related to changes in innate and adaptive immune system. Those age-related changes could 
be associated with susceptibility to infectious diseases, Alzheimer’s disease, autoimmunity, osteopo-
rosis, and cancer (1).
However, several potentially confounding factors make it difficult to draw a clear picture of causal 
relationships. For example, the risk of cancer increases with age and cancer itself. Cancer treatment 
could also influence the immune system and chronic infections such as cytomegalovirus (CMV) 
could drive immunosenescence. These processes occur simultaneously; nevertheless, it is not yet 
determined in what magnitude they are causally related (2).
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The changes most consistently found in immunosenescence 
studies pertain to CD8+ T cells. It is well documented that with 
decrease in age naïve CD8+ T cells, highly differentiated CD8+ 
T cells lacking CD28 accumulate and those CD8+CD28− T cells 
upregulate the expression of CD45RA. Additionally, these cells 
show signs of replicative senescence such as a decreased prolif-
eration ability, shortened telomeres, impairment of telomerase 
activity, and upregulation of CD57 (3, 4). These facts have been 
frequently associated with chronic CMV infection (5).
The relationship between these changes and a susceptibility to 
disease was first documented in the Swedish octogenarian study 
(OCTO-immune). This study defined the concept of “immune 
risk profile” (IRP). The IRP was described as a decrease in number 
and frequency of B cells, an increased count of CD8+ memory T 
cells, a CD4/CD8 ratio of less than 1, and a rise of CD8+CD28− 
among other late-stage differentiated T cells (6). Additionally, 
most of these late-stage differentiated cells express CD57 (7). The 
IRP was also associated with high serum concentrations of pro-
inflammatory cytokines and seropositivity to CMV (6, 8).
High prevalence of CMV is found worldwide; however, it 
fluctuates depending on the region (9). The CMV infection 
frequently starts during adolescence and persists throughout life. 
The expansion of CD8+CD28− T cells upregulating CD57 has 
been associated with CMV infection. It is considered one of the 
main causes of immunosenescence (8).
A possible connection between the high prevalence of CMV 
infection in tropical countries and some sociocultural behaviors, 
which contribute to CMV transmission in early stages of life, has 
been postulated (10). Our group confirmed a high seroprevalence 
of CMV infection in healthy Cubans from an early age (4).
In the present paper, the current knowledge on the dynamics 
of T cell subpopulations during aging is reviewed, as well as the 
relationship with CMV infection, cancer, and cancer treatment. 
The results of several studies carried out in Cuba are also inter-
preted. As Cuban population presents an unusual combination 
of a long life expectancy and high antigenic load of a tropical 
country, it is a kind of natural experiment, which could show 
novel aspects in the relationships between immunosenescence 
and chronic non-communicable diseases.
THe inCReASeD PROPORTiOn OF  
LATe-DiFFeRenTiATeD CD8 T CeLLS in 
HeALTHY CUBAnS iS inFLUenCeD 
BY AGe AnD GenDeR
Long-lasting antigenic stimulation causes the progressive increase 
of late-stage differentiated, oligoclonal T cells, mainly, but not 
exclusively, within the CD8+ T cell compartment. Increasing 
evidence demonstrate that the CD8+CD28− and CD8+CD57+ T 
cell populations play an essential role in innumerable diseases 
or chronic inflammation-related conditions, associated with 
chronic immune stimulation such as cancer, chronic intracellular 
infections, chronic pulmonary diseases, autoimmune diseases, 
and allogeneic transplantation (11).
Older individuals tend to exhibit abundance of late-stage 
differentiated memory T cells. CD57 is a receptor expressed 
on CD8+ and CD4+ T cells in late stages of differentiation (12). 
Late-differentiated T cells are characterized by the expression of 
CD45RO, reduced or almost undetectable expression of costimu-
latory molecules CD27 and CD28, and chemokine receptor 
CCR7. The re-expression of CD45RA is also characteristic (13).
Previous reports confirmed that CD57+CD8+ T cells can be 
defined as “replicatively senescent cells,” although these cells are 
not “functionally exhausted” (13). The progressive decrease of 
T cell function as a consequence of a chronically high antigen 
load is described as part of the phenomenon of exhaustion (14). 
Nevertheless, senescent CD57+CD8+ T cells are able to secrete 
TNF-α and IFN-γ upon encounter with antigen (15).
CD8+CD28− T cells are end-stage cells that have lost the 
expression of CD28. Lin and colleagues showed that they had the 
lowest telomerase activity among memory and highly differen-
tiated CD8+ T cell subsets. Consistent with this finding, those 
researchers also demonstrated that CD8+CD28− T cells had “the 
shortest mean telomere length” among the studied groups of 
memory T cells (16).
Prior studies suggest that the replicative capacity of 
CD8+CD28− T cells in response to antigen stimulation is signifi-
cantly reduced and the telomere length is shorter in comparison 
with CD8+CD28+ T cells (17). High percentages of CD8+CD28− T 
cells are related to reduced response to vaccination (18) and have 
been associated with mortality in a cohort of elderly Swedish (19).
A study in healthy Cubans showed an effect of gender in the 
dynamics of T cell subpopulations during aging. Although the 
proportion of late-differentiated CD8+CD28− and CD8+CD57+ 
T cells increased with age, it was only statistically significant in 
males. Cuban women preserve the proportion of CD8+CD28− 
and CD8+CD57+ T cells practically constant at all ages. Our 
group also reported other changes with age within the CD8+ T 
cell subset. In this occasion, an increased frequency of terminally 
differentiated CD8+CD45RA+CD28− T cells was found in females 
as they aged, while males showed higher frequency of these cells 
from youth. By contrast, within CD4+ T lymphocytes, terminally 
differentiated CD4+CD45RA+CD28− T cells showed an age-
associated increase in both sexes, though higher proportions 
were found in males (4).
The detection of differences concerning the structure and 
function of the immune system in males and females has been 
described (20, 21). In addition to hormones, genetic factors can 
determine the differences in the immune response between males 
and females. The fact that some genes in the X chromosome are 
involved in immunity has been addressed (21). It has also been 
proposed that estrogens improve humoral immunity, whereas 
androgens and progesterone have a tendency to hamper it (22).
Gender differences in the immune system have been evi-
denced also in epidemiological studies showing higher incidence 
of autoimmune diseases in females and higher rate of chronic 
inflammatory illness such as atherosclerosis-related diseases in 
males. Nevertheless, the interaction among hormones, genetics, 
inflammation, and immune system presents a complex scenario 
that must be more intensively studied (4).
The influence of gender in immunosenescence also appeared 
in the Berlin Aging Study II, which reported gender-related dif-
ferences concerning the consequences of age and CMV infection 
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on CD4 and CD8 T cells. This study reported that older men 
showed higher frequencies of late-differentiated CD8+CD57+ T 
cells and concluded that in elderly men, the “CMV-associated 
senescence of T cells” was more pronounced than in elderly 
women (23).
The Berlin study also showed a strong effect of CMV infection 
in the appearance of CD45RA+CCR7−CD27−CD28− terminally 
differentiated T cells (so-called TEMRA). They observed a signifi-
cantly lower proportion of CD4+CD45RA+CCR7−CD27−CD28− T 
cells in CMV-negative individuals than in CMV-positive indi-
viduals, regardless of gender and age. Concerning the frequency 
of CD8+ T cells, age was observed to have a significant influence, 
but here too, it was only significant in subjects with demonstrated 
CMV infection. Therefore, frequency of terminally differentiated 
T cells was significantly higher in CMV-positive elderly indi-
viduals than it was in CMV-negative elderly, notwithstanding 
gender (23).
Cytomegalovirus is a common herpes virus affecting the 
60–90% of the global population. The prevalence of infected indi-
viduals increases with age. It is expected that 90% of individuals 
could be infected nearby the 90 decade of life in contrast with the 
evidence of 40–60% of individuals in the middle age population 
(24). The OCTO study reported that the prevalence of subjects 
with CMV–IgG antibodies in individuals older than 80 years was 
around 90%, while in middle-aged individuals, it was relatively 
consistent at 67% (6). Interestingly, our group reported a high 
seroprevalence of CMV seropositivity greater than 80% in Cuban 
healthy population from young ages (4).
Persistent infection with viruses such us CMV can augment 
the accumulation of senescent CD4+ and CD8+ T cells, identified 
as CD27−CD28−CD45RA+KLRG1+ and CD57+, compared to 
age-matched seronegative individuals (25). The research in this 
area has been predominantly focused on CD8+ T cells, which 
display decreased naive populations and increased memory 
subset distribution consistent with a more memory/late effector 
cell profile. This is accompanied by changes in function such as 
reduced proliferative capacity, especially in CD57+ T cells, and 
increased cytotoxic and secretory functions (26, 27).
However, changes in T cell subpopulations are also evident 
in CD4+ T lymphocytes. A recent work described the significant 
increment in the percentages of CD4+CD57+ T cells in young 
CMV-positive individuals, compared with young CMV-negative 
individuals. They showed that CD4+ T cells that coexpress CD57 
and CD154 are only present in CMV-positive subjects and are 
considered a very polyfunctional CD4+ subset (28). This group 
had previously revealed an increase in CD8+CD57+ T cells in 
CMV-positive young subjects (29).
The CMV-IgG seropositivity was determined in healthy 
Cubans of all ages in a study conducted by Garcia and colleagues. 
The general seroprevalence of CMV seropositivity was 90%. More 
than 90% of elderly individuals had antibodies against CMV, 
notwithstanding their gender. Nevertheless, young males (93.3%) 
had higher seroprevalence than young females (73.6%) (4).
In our analysis, the higher percentage of CD45RA+CD28− T 
cells within the CD4+ and CD8+ subsets described in Cuban 
males, but not in females, during young ages can be explained 
by the differential effect of gender and age in the thymic output 
(4). Furthermore, since androgens and testosterone have higher 
association with severe thymus involution than female hormones, 
young males could have less protected immune system than 
females. This combined with exposure to high antigenic loads 
since early ages could have driven immunosenescence in young 
males (4, 30).
The thymic involution in elderly people induces a reduction 
of naive T cells in the periphery, regardless of CMV infection. 
Nonetheless, during persistent CMV infection, the memory T 
cells frequency is higher, possibly because of the latency of CMV, 
which exerts a persistent stimulation on the immune system in 
order to control the virus (24, 26). Additionally, CMV reactivation 
may occur more often in older people (31). From this point, an 
impairment of the immune system would hamper its capacity to 
control the CMV infection; therefore, a reactivation of the CMV 
would lead to a long-lasting antigen stimulation and accelerate 
the accumulation of CD28− T cells as well as the emergence of 
the phenomenon of immunosenescence, functioning as a closed 
loop (24).
TReATMenT wiTH PLATinUM-BASeD 
CHeMOTHeRAPY enTAiLS DiFFeRenT 
PATTeRnS OF TeRMinALLY 
DiFFeRenTiATeD CD8 T CeLLS in 
nSCLC PATienTS
Around 70% of cancer-related deaths and 60% of new cancer 
diagnosis occur in patients older than 65 years (1). Moreover, as 
aging is a global phenomenon, a rapid increase in elderly with 
malignancies is expected (32).
A study in cancer patients (respiratory, digestive, reproductive, 
head, and neck) showed an expansion of CD8+CD28− T cells in 
heavy chemo-treated patients compared with healthy volunteers 
and treatment-naive patients (33). Another research in patients 
with various forms of lung cancer receiving chemotherapy 
reported higher proportions of CD28−CD57+ cells, thereby high-
lighting the most pronounced changes in lung cancer patients 
with stage IV of the disease (34).
Recently, high proportions of CD4+CD28− and CD4+CD57+ T 
cells have been reported in CMV-positive glioblastoma patients. 
Additionally, these researchers described short survival in 
glioblastoma patients with high proportions of CD4+CD28− and 
CD4+CD57+CD28 null T cells, thereby suggesting an associa-
tion between those immunosenescence markers and survival in 
CMV-positive glioblastoma patients (35).
Our group evaluated the presence of the CD28 receptor 
on CD4+ and CD8+ T cells in a cohort of Cuban advanced 
NSCLC patients, before and after administration of first-line 
platinum-based chemotherapy. We found that the proportion of 
CD4+CD28− T cells significantly increased in NSCLC patients 
after treatment with platinum-based chemotherapy, compared 
with healthy volunteers and with cancer patients without 
chemotherapy. Healthy volunteers and cancer patients without 
chemotherapy had low proportions of CD8+CD28− T cells. 
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Cancer patients treated with standard front-line chemotherapy 
showed the highest proportions of CD8+CD28− T cells (36).
In addition, our group investigated the frequency of 
CD8+CD57+ T cells and CD45RA+CD28− on CD4+ and CD8+ T 
cells in Cuban NSCLC patients after front-line platinum-based 
chemotherapy. We showed that the frequency of CD8+CD57+, 
CD4+CD45+CD28−, and CD8+CD45+CD28− T cells remained 
unchanged, regardless of the presence of cancer itself or the 
chemotherapy treatment.
Based on the high prevalence of CMV infection in Cubans 
and on previous findings in healthy elderly (4), we hypoth-
esized that notwithstanding cancer disease or chemotherapy, 
aging and possibly chronic CMV infection could be the main 
causes for the increase of CD45RA+CD28− T cells (36). In our 
opinion, platinum-based chemotherapy probably causes only 
the increase of CD28− T cell subpopulations within CD4+ and 
CD8+ subsets. Otherwise, changes in the frequency of CD4+ or 
CD8+CD45RA+CD28− and CD57+CD8+ T cells seems not to be 
related with cancer disease or chemotherapy.
Although consensus about necessary chronic antigen stimu-
lation, especially CMV, to cause immunosenescence is under 
constant discussion, maintaining CMV reactivations under 
control requires a huge effort from the immune system. This virus 
could be responsible for the functional impairment of many 
cell types from innate and adaptive immune systems. Besides 
affecting the immunosurveillance, this virus could also contrib-
ute to the pathogenesis of some inflammatory diseases and even 
cancer (24).
CD8+CD28− T CeLLS AnD CD4/CD8 
RATiO AS PReDiCTive BiOMARKeRS OF 
eFFiCACY OF THeRAPeUTiC 
vACCinATiOn wiTH THe ePiDeRMAL 
GROwTH FACTOR (eGF)-BASeD vACCine 
CiMAvax-eGF
The suppression induced by tumor disease and by standard 
therapies such as chemotherapy and radiation can influence det-
rimentally the immune system of cancer patients. Nowadays, the 
assessment of a patient’s immune status represents a valuable tool 
for determine patients for undergoing immunotherapy (37, 38).
Biomarkers are becoming more necessary in order to select 
patients who could benefit from therapies, either in the initial 
phase of the disease or in advanced cancer stages. In such cases, 
the definition of personalized treatments in tumor disease could 
lead to an improvement of therapeutic success (39).
CIMAvax-EGF is a therapeutic cancer vaccine developed to 
generate specific humoral response against the EGF (40). More 
than 4,000 advanced NSCLC patients have been treated with the 
CIMAvax-EGF vaccine, which is safe and immunogenic and have 
proved its efficacy (41).
As previous results published by our Institute showed, a 
relation between the magnitude of specific anti-EGF antibody 
response and the clinical outcomes of vaccinated patients has been 
demonstrated when using CIMAvax-EGF as switch maintenance 
therapy after platinum-based first-line chemotherapy in NSCLC 
patients. Young patients showed the best clinical results (42, 43). 
These results suggest that the clinical benefit in CIMAvax-EGF 
vaccinated NSCLC patients goes together with the development 
of a good specific humoral response (36).
In a recent article, our group proposed the frequencies of 
CD8+CD28− T cells and the CD4/CD8 ratio as possible predictive 
biomarkers for the CIMAvax-EGF efficacy. Consequently, NSCLC 
patients with a proportion of CD8+CD28− T cells of less than 24% 
and a CD4/CD8 ratio >2 determined after front-line standard 
chemotherapy and prior to vaccination with CIMAvax-EGF 
achieved a median survival superior by almost 20 months to that 
of vaccinated patients with more than 24% of CD8+CD28− T cells 
and a CD4/CD8 ratio <2. These findings emphasize the impact 
of the immune status on the clinical evolution of CIMAvax-EGF 
vaccinated NSCLC patients and validate the usefulness of late-
stage differentiated CD8+ T cells as predictive biomarkers for the 
CIMAvax-EGF efficacy (36).
As studies of the senescence of the immune system advance, 
it can be predicted that markers of the dynamics of lymphocytes 
and cytokines along individual’s lifetime will be increasingly used 
as prognostic factors and treatment predictors in several diseases. 
In contrast to genetic markers, which are mainly endogenous 
individual traits, markers of immunosenescence evolve under 
extrinsic environmental influences, which obviously vary among 
diverse human groups. Thus, findings are difficult to extrapolate 
from country to country. For this reason, specific studies in 
diverse populations are needed to better asses the timelines of 
immunosenescence and the influence of chronic antigenic loads 
and gender. It has been predicted that different forms of immu-
notherapy will become part of the main therapeutic strategy 
in an increasing fraction of cancer patients in the near future. 
This scenario will make specific studies of immunosenescence 
mandatory.
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